Peptides for longevity: what the research shows, tier by tier

No peptide is proven to extend human lifespan, but a few have real human data on outcomes that matter for healthy ageing. The strongest is semaglutide (Wegovy), an approved peptide drug: in a trial of 17,604 adults with heart disease and overweight, heart attacks, strokes and cardiovascular deaths fell to 6.5% versus 8.0% on placebo (Lincoff 2023, Human RCT). Elamipretide is approved only for Barth syndrome. Epitalon, MOTS-c, humanin and FOXO4-DRI are unapproved; their longevity evidence is mostly animal or lab work.

Peptide	US FDA and compounding status	WADA (2026 List; 2027 List from 2027-01-01)
Semaglutide (Wegovy)	Approved; since 2024-03-08 also to reduce cardiovascular death, heart attack and stroke in adults with cardiovascular disease and obesity or overweight (FDA)	Not prohibited (USADA); in the 2027 Monitoring Program, which is not a ban (USADA 2027 advisory)
Elamipretide (Forzinity)	Accelerated approval 2025-09-19 for muscle strength in Barth syndrome only (label); not on FDA’s compounding category lists	Approved by a health agency, so outside S0 (our reading of the S0 definition)
MOTS-c	Not approved; listed by FDA as nominated but withdrawn from Category 2 (FDA); PCAC voted 7–5 (2 abstentions) on 2026-07-23 to recommend 503A listing for obesity and osteoporosis, as reported by trade press; advisory, no FDA rule yet (meeting page)	Prohibited at all times, S4.4.1 metabolic modulators (USADA)
Epitalon	Not approved; nominated but withdrawn from Category 2; PCAC voted 7–4 on 2026-07-24 to recommend 503A listing for insomnia, as reported by trade press; advisory, no FDA rule yet	2026 List: S0 covers non-approved substances (our reading of USADA’s S0 definition). From 2027, S0 names “peptides” in general, prohibited at all times
Humanin, FOXO4-DRI	Not approved; not on FDA’s Category 2 page	S0 as non-approved peptides (our reading; “peptides” named in S0 from 2027)
Strongest evidence	Human RCT, n=17,604 (semaglutide, cardiovascular outcomes)	—
Human trials	SELECT: NCT03574597; elamipretide in older adults: NCT07275424; MOTS-c analogue CB4211: NCT03998514 (no results posted); epitalon: NCT07888595	—
Last checked	2026-11-06	—

Peptides for longevity, ranked by evidence

This roundup orders each peptide by the strongest evidence it has on outcomes linked to ageing: approved drugs with human trials first, then unapproved peptides with human data, then peptides tested only in animals or cells. Results come from different trials in different groups, so they are cross-trial findings and cannot be ranked against each other directly. “Longevity” here means healthspan outcomes such as heart events, frailty or physical capacity; no study below measured human lifespan as such.

Peptide	Best evidence	Key finding
Semaglutide	Human RCT (n=17,604)	Heart events 6.5% vs 8.0%, HR 0.80 (Lincoff 2023)
Elamipretide	Human RCT (n=39 older adults)	Short-lived rise in muscle ATP capacity (Roshanravan 2021)
Epithalamin (extract)	Human controlled study (n=266)	Lower mortality over 6–8 years, one group (Khavinson 2003)
Epitalon	Lab (human cells)	Longer telomeres via telomerase (Al-Dulaimi 2025)
MOTS-c	Animal (old mice)	More physical capacity and healthspan (Reynolds 2021)
Humanin	Animal (worms, mice)	Longer worm lifespan; better metabolic markers in mice (Yen 2020)
FOXO4-DRI	Animal (aged mice)	Cleared senescent cells; fitness, fur and kidney function restored (Baar 2017)

Tier 1: semaglutide, the longevity-relevant benefits with the strongest data

Semaglutide is a GLP-1 receptor agonist, a peptide drug that mimics a gut hormone. It has the largest outcome trial of any peptide in this roundup, on heart attacks, strokes and cardiovascular deaths. In SELECT, 17,604 adults aged 45 or older with existing cardiovascular disease, a body-mass index of 27 or more and no diabetes were randomized to weekly semaglutide 2.4 mg or placebo and followed for a mean of 39.8 months (Lincoff 2023, Human RCT). Cardiovascular death, heart attack or stroke occurred in 6.5% on semaglutide and 8.0% on placebo (hazard ratio 0.80; P<0.001). FDA added that heart-protection use to the Wegovy label on 2024-03-08 (FDA).

The ageing angle is clearer in a 2026 analysis of the same trial by frailty, a score that counts age-related health deficits (Ostrominski 2026, secondary analysis of a Human RCT). The mean age was 61.6 years, and 22% of participants were in the most frail group. Semaglutide reduced all-cause mortality, heart failure events and all-cause hospitalization whatever the frailty level. Over 104 weeks, a participant’s frailty category was more likely to improve (odds ratio 2.46) and less likely to worsen (odds ratio 0.47) than on placebo, and quality-of-life gains looked larger in frailer people.

The limits matter. These results apply to people with heart disease and excess weight, not to healthy adults taking a drug “for longevity”. Side effects are common: 16.6% stopped semaglutide because of adverse events, against 8.2% on placebo. Our peptides vs Ozempic guide compares it with the research peptides marketed as alternatives.

Tier 1: elamipretide (SS-31), approved for one rare disease and tested in older adults

Elamipretide, also known as SS-31, is a small peptide that binds cardiolipin, a lipid in the mitochondria, the parts of cells that make energy; its label calls it a “mitochondrial cardiolipin binder”. FDA granted it accelerated approval as Forzinity on 2025-09-19, only to improve muscle strength in people with Barth syndrome weighing at least 30 kg (Forzinity label). The approval rests on knee-muscle strength, an intermediate endpoint, and depends on a confirmatory trial.

Its most promising ageing result is small and short. In a randomized, placebo-controlled trial in 39 healthy adults aged 60 to 85 with poorly working mitochondria, one 2-hour infusion gave a borderline rise in the hand muscle’s maximum ATP (energy) production right after dosing (P=0.045 for the percent change) (Roshanravan 2021, Human RCT, n=39). By day 7 there was no difference, and fatigue resistance did not change. The study was funded by the drug’s developer. In aged mice, 8 weeks of elamipretide slowed frailty and partly restored heart strain and muscle fatigue resistance, yet epigenetic markers of biological age did not change in most groups (Mitchell 2025, Animal). A 30-person open-label safety study of daily elamipretide in healthy older adults is recruiting (NCT07275424). The label’s most common side effect is injection-site reactions. For how it compares with other mitochondrial options, see MOTS-c vs SS-31 vs NAD+.

Tier 2: epitalon and epithalamin, old human data and new lab data

Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) built from the composition of epithalamin, a chemically distinct extract of animal pineal glands (Jain 2026, narrative review). The two are often confused, and most of the human “lifespan” claims belong to the extract.

The encouraging human figures come from one research group. In 266 older people followed for 6 to 8 years, mortality was 1.6- to 1.8-fold lower with epithalamin and 2.5-fold lower with epithalamin plus the thymus extract thymalin than in controls (Khavinson 2003, Human controlled study, n=266). A 12-year randomized study in older patients with coronary disease, co-authored by the same group, reported 28% fewer deaths with epithalamin (Korkushko 2006, Human RCT, size not given in the abstract). Earlier, epithalamin lengthened mean lifespan by 11–31% in fruit flies, mice and rats, though not in one mouse strain (Anisimov 1998, Animal).

For synthetic epitalon itself, a 2025 study found dose-dependent telomere lengthening in normal human cells through telomerase, and lengthening in breast cancer cell lines through a separate mechanism (Al-Dulaimi 2025, Lab). The 2026 review concludes that epitalon is “biologically active but clinically unproven”: human data are limited to small biomarker studies, and long-term safety, including cancer questions, is unresolved. The only registered study listing epitalon is a 48-person early phase 1 test of a topical peptide serum on skin ageing clocks (NCT07888595; ClinicalTrials.gov, searched 2026-11-06). Its sleep research is covered in peptides for sleep: DSIP vs epitalon vs pinealon.

Tier 2: MOTS-c, promising mouse healthspan data, no human results yet

MOTS-c is a peptide encoded in mitochondrial DNA that acts on muscle metabolism. In mice, it improved physical performance in young, middle-aged and old animals, and intermittent treatment started late in life (23.5 months) increased physical capacity and healthspan (Reynolds 2021, Animal). The same study found that exercise raises the body’s own MOTS-c in human muscle and blood, which links it to a known healthy-ageing habit. Two of its authors were consultants and shareholders of CohBar, Inc.

USADA states there are “no completed human clinical trials” of MOTS-c (USADA). A phase 1a/1b study of CB4211, which its developer calls “a novel and improved analog of MOTS-c” (CohBar 10-K), finished in 2021 with 88 participants (NCT03998514). The company reported that CB4211 was well tolerated with no serious adverse events, but the registry shows no posted results (checked 2026-11-06). No completed trial of MOTS-c itself with posted results was found on ClinicalTrials.gov (searched 2026-11-06). Our MOTS-c vs 5-Amino-1MQ comparison covers its metabolic research in more depth.

Tier 3: humanin, FOXO4-DRI and GHK-Cu, animal and cosmetic evidence

Humanin is another mitochondria-derived peptide. Overexpressing it lengthened lifespan in the worm C. elegans, and a potent analogue (HNG) given to middle-aged mice improved metabolic health markers and lowered inflammation (Yen 2020, Animal). In people, children of centenarians had much higher blood humanin than age-matched controls, an association that does not show humanin causes long life (Human observational). No registered trial giving humanin to people was found on ClinicalTrials.gov (searched 2026-11-06).

FOXO4-DRI is a designed peptide that blocks a protein interaction senescent (“zombie”) cells need to survive. In fast-ageing and naturally aged mice it triggered death of senescent cells and restored fitness, fur density and kidney function (Baar 2017, Animal). No human trial was found on ClinicalTrials.gov (searched 2026-11-06).

GHK-Cu, a copper peptide, falls in the blood with age; a review reports that cosmetic products containing it reduced fine lines and wrinkles and improved skin firmness (Pickart 2015, review). That is skin ageing, not lifespan; the details are in our GHK-Cu results timeline.

Can longevity peptides be combined?

No controlled human study of any two of these peptides combined for ageing was found on PubMed or ClinicalTrials.gov (searched 2026-11-06). The one registered study that mixes peptides, NCT07888595, applies a topical serum to skin and measures biological-age clocks; it has not reported results. Each combination therefore rests on the separate, mostly animal, evidence above.

Safety and regulatory status

United States. Semaglutide is approved; its common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache and fatigue (FDA). Elamipretide is approved only for Barth syndrome; its label warns about benzyl alcohol toxicity in newborns and allergic reactions (label). MOTS-c, epitalon, humanin and FOXO4-DRI have no FDA approval for any use (Drugs@FDA data via openFDA, searched 2026-11-06). FDA lists MOTS-c, epitalon and GHK-Cu among substances whose nominators withdrew them from Category 2 (FDA, page current 04/22/2026). FDA’s compounding advisory committee reviewed MOTS-c for obesity and osteoporosis and epitalon for insomnia in July 2026; the votes, reported by trade press as 7–5 and 7–4 in favor, are advisory, and FDA has posted no vote results or minutes (FDA meeting page). Neither is on the 503A bulks list in 21 CFR 216.23 (eCFR, as of 2026-11-04).

Unknowns. For the unapproved peptides there are no adequate long-term human safety data, and the epitalon review flags cancer and immune-reaction questions as unresolved (Jain 2026). Telomerase activation, the proposed epitalon mechanism, also occurred in cancer cell lines in the lab study.

Athletes. MOTS-c is prohibited at all times under S4.4.1 (USADA). From 2027-01-01, the WADA List names “peptides” in general under S0, prohibited at all times, which covers unapproved peptides such as epitalon (USADA 2027 advisory). GLP-1 drugs are not prohibited (USADA).

Anyone who suspects a side effect from a longevity peptide or any other drug or product can report it to the FDA through MedWatch.